【佳學基因檢測】腫瘤內異質性對治療分層的影響

千萬不要做基因檢測合理嗎

挖掘記錄《J Pathol》在?2014 Jan;232(2):264-73發(fā)表了一篇題目為《腫瘤內異質性對治療分層的影響》腫瘤靶向藥物治療基因檢測臨床研究文章。該研究由Andrew Crockford,?Mariam Jamal-Hanjani,?James Hicks,?Charles Swanton等完成。促進了腫瘤的正確治療與個性化用藥的發(fā)展，進一步強調了基因信息檢測與分析的重要性。

腫瘤靶向藥物及正確治療臨床研究內容關鍵詞：

瘤內異質性,源自患者的異種移植模型,個性化醫(yī)療。

腫瘤靶向治療基因檢測臨床應用結果

盡管癌癥的診斷和治療取得了進展，但大多數(shù)晚期轉移性實體瘤仍然無法治好。個體腫瘤內的差異基因表達、體細胞突變狀態(tài)、腫瘤特異性遺傳特征和微環(huán)境選擇壓力對指導治療干預的預測分析的成功具有影響。在這篇綜述中，我們討論了遺傳和表型異質性的證據(jù)及其對臨床決策的潛在影響。我們強調了可以改進的研究領域，以便更好地對患者治療進行分層。我們還討論了患者衍生的腫瘤反應模型的預測潛力，包括腫瘤內異質性背景下的異種移植和基于細胞系的系統(tǒng)。

腫瘤發(fā)生與反復轉移國際數(shù)據(jù)庫描述：

Despite advances in the diagnosis and treatment of cancer, the majority of advanced metastatic solid tumours remain incurable. Differential gene expression, somatic mutational status, tumour-specific genetic signatures and micro-environmental selection pressures within individual tumours have implications for the success of predictive assays to guide therapeutic intervention. In this review we discuss the evidence for genetic and phenotypic heterogeneity and its potential implications for clinical decision making. We highlight areas of research that could be improved in order to better stratify patient treatment. We also discuss the predictive potential of patient-derived models of tumour response, including xenograft and cell line-based systems within the context of intratumour heterogeneity.